In this article LLY NOVO.B-DK ZEAL-DK ALT VKTX GILD ORCL Follow your favorite stocks CREATE FREE ACCOUNT An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.
Brendan McDermid | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Eli Lilly , Novo Nordisk and other drugmakers showed off encouraging data on weight loss and diabetes drugs last week. Companies shared results at the American Diabetes Association's annual meeting in Orlando, Florida, the world's biggest scientific conference focused on diabetes research, prevention and care.
The drug developments come amid growing investor interest in the treatment of metabolic diseases and specifically, a buzzy class of medications called GLP-1s But drugmakers presented treatments that use different approaches than traditional GLP-1s such as Novo Nordisk's popular weight loss injection Wegovy and diabetes counterpart Ozempic. The two medications mimic a hormone produced in the gut to suppress a person's appetite. Companies are also pivoting away from focusing on weight loss alone in trials.
Some drugmakers are examining their drugs' potential to treat other health conditions, while others are seeing whether a medication can preserve lean muscle mass in patients while also promoting weight loss. Here are a few of the highlights from the conference: Eli Lilly released additional data from two late-stage clin.
